Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
Mirum Pharmaceuticals (NASDAQ: MIRM) reported strong financial results for Q4 and full-year 2024, with total net product sales reaching $336.4 million, up from $178.9 million in 2023. The company provided guidance for 2025, expecting global net product sales of $420-435 million.
LIVMARLI sales contributed $213.3 million in 2024, while Bile Acid Medicines generated $123.1 million. The global LIVMARLI business expanded to 30 countries, including successful launches in major European markets.
Key pipeline developments include expected completion of the VISTAS study enrollment for volixibat in PSC during H2 2025, with topline data in 2026. The company reported $292.8 million in cash and investments as of December 31, 2024, compared to $286.3 million at the end of 2023.
Mirum Pharmaceuticals (NASDAQ: MIRM) ha riportato risultati finanziari solidi per il quarto trimestre e per l'intero anno 2024, con vendite nette totali di prodotti che hanno raggiunto $336,4 milioni, in aumento rispetto ai $178,9 milioni del 2023. L'azienda ha fornito indicazioni per il 2025, prevedendo vendite nette globali di prodotti comprese tra $420-435 milioni.
Le vendite di LIVMARLI hanno contribuito con $213,3 milioni nel 2024, mentre i farmaci a base di acidi biliari hanno generato $123,1 milioni. Il business globale di LIVMARLI si è espanso in 30 paesi, con lanci di successo nei principali mercati europei.
Tra i principali sviluppi della pipeline ci sono il completamento previsto dell'arruolamento nello studio VISTAS per volixibat in PSC durante il secondo semestre del 2025, con dati preliminari attesi nel 2026. L'azienda ha riportato $292,8 milioni in contante e investimenti al 31 dicembre 2024, rispetto ai $286,3 milioni alla fine del 2023.
Mirum Pharmaceuticals (NASDAQ: MIRM) reportó resultados financieros sólidos para el cuarto trimestre y el año completo 2024, con ventas netas totales de productos alcanzando $336.4 millones, un aumento desde los $178.9 millones en 2023. La compañía proporcionó orientación para 2025, esperando ventas netas globales de productos de $420-435 millones.
Las ventas de LIVMARLI contribuyeron con $213.3 millones en 2024, mientras que los medicamentos de ácidos biliares generaron $123.1 millones. El negocio global de LIVMARLI se expandió a 30 países, incluyendo lanzamientos exitosos en los principales mercados europeos.
Los desarrollos clave de la pipeline incluyen la finalización esperada de la inscripción del estudio VISTAS para volixibat en PSC durante el segundo semestre de 2025, con datos preliminares en 2026. La compañía reportó $292.8 millones en efectivo e inversiones al 31 de diciembre de 2024, en comparación con los $286.3 millones a finales de 2023.
Mirum Pharmaceuticals (NASDAQ: MIRM)는 2024년 4분기 및 연간 강력한 재무 결과를 보고했으며, 총 순 제품 판매는 $336.4 백만에 달해 2023년의 $178.9 백만에서 증가했습니다. 이 회사는 2025년을 위한 가이드를 제공하며, 글로벌 순 제품 판매를 $420-435 백만으로 예상하고 있습니다.
LIVMARLI 판매는 2024년에 $213.3 백만을 기여했으며, 담즙산 의약품은 $123.1 백만을 생성했습니다. LIVMARLI의 글로벌 비즈니스는 30개국으로 확장되었으며, 주요 유럽 시장에서 성공적인 출시가 이루어졌습니다.
주요 파이프라인 개발에는 2025년 하반기 PSC에서 volixibat에 대한 VISTAS 연구 등록 완료가 예상되며, 2026년에 주요 데이터가 제공될 예정입니다. 이 회사는 2024년 12월 31일 기준으로 $292.8 백만의 현금 및 투자금을 보고했으며, 이는 2023년 말의 $286.3 백만과 비교됩니다.
Mirum Pharmaceuticals (NASDAQ: MIRM) a annoncé de solides résultats financiers pour le quatrième trimestre et l'année complète 2024, avec des ventes nettes totales de produits atteignant $336,4 millions, en hausse par rapport à $178,9 millions en 2023. L'entreprise a fourni des prévisions pour 2025, s'attendant à des ventes nettes mondiales de produits de $420-435 millions.
Les ventes de LIVMARLI ont contribué à hauteur de $213,3 millions en 2024, tandis que les médicaments à base d'acides biliaires ont généré $123,1 millions. L'activité mondiale de LIVMARLI s'est étendue à 30 pays, y compris des lancements réussis sur les principaux marchés européens.
Les développements clés de la pipeline incluent l'achèvement prévu de l'inscription à l'étude VISTAS pour volixibat dans le PSC au second semestre 2025, avec des données préliminaires attendues en 2026. L'entreprise a rapporté $292,8 millions en liquidités et investissements au 31 décembre 2024, contre $286,3 millions à la fin de 2023.
Mirum Pharmaceuticals (NASDAQ: MIRM) berichtete über starke Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024, mit einem Gesamtumsatz aus Produktverkäufen von $336,4 Millionen, ein Anstieg von $178,9 Millionen im Jahr 2023. Das Unternehmen gab eine Prognose für 2025 ab und erwartet globale Netto-Produktverkäufe von $420-435 Millionen.
Die Verkäufe von LIVMARLI trugen mit $213,3 Millionen im Jahr 2024 bei, während die Arzneimittel auf Basis von Gallensäuren $123,1 Millionen generierten. Das globale Geschäft von LIVMARLI expandierte auf 30 Länder, einschließlich erfolgreicher Markteinführungen in wichtigen europäischen Märkten.
Wichtige Entwicklungen in der Pipeline umfassen den voraussichtlichen Abschluss der Einschreibung der VISTAS-Studie für volixibat bei PSC im zweiten Halbjahr 2025, mit den wichtigsten Daten im Jahr 2026. Das Unternehmen berichtete am 31. Dezember 2024 von $292,8 Millionen an Bargeld und Investitionen, verglichen mit $286,3 Millionen Ende 2023.
- Net product sales grew 88% YoY to $336.4M
- Strong 2025 revenue guidance of $420-435M
- LIVMARLI expansion to 30 countries globally
- Volixibat received FDA breakthrough therapy designation for PBC
- Cash position increased to $292.8M from $286.3M YoY
- Operating expenses increased 44% to $424.5M
- Operating expenses exceeded revenue by $88.1M
Insights
Mirum Pharmaceuticals delivered exceptional financial performance in 2024 with
The company's 2025 revenue guidance of
While operating expenses increased to
Mirum's global expansion strategy is bearing fruit with LIVMARLI now available in 30 countries. Securing reimbursement in Europe's four major markets is particularly significant as these regions typically have stringent health technology assessment processes, validating both clinical efficacy and economic value.
The pipeline continues to advance with several key catalysts ahead. The breakthrough therapy designation for volixibat in PBC could accelerate its path to market, while the VISTAS study in PSC addresses a condition with no approved therapies. The expanded indications for LIVMARLI in PFIC create additional revenue opportunities in ultra-rare patient populations with high unmet needs.
The in-licensing of MRM-3379 for Fragile X Syndrome represents a strategic expansion beyond liver diseases into neurological disorders, potentially opening new growth avenues while leveraging the company's rare disease expertise.
Mirum Pharmaceuticals continues to establish itself as a leading rare liver disease company with a diversified portfolio addressing significant unmet needs. The remarkable commercial performance of LIVMARLI (
The expanded regulatory approvals for LIVMARLI are particularly significant as they allow treatment of younger PFIC patients (12 months+ in US, 3 months+ in Europe), addressing this devastating disease earlier when intervention may be most impactful. These label expansions effectively increase the addressable patient population while reinforcing LIVMARLI's clinical utility across cholestatic conditions.
Volixibat's breakthrough therapy designation in PBC represents a important regulatory advantage that could accelerate approval by 2-3 years and provide enhanced FDA interactions. This designation is only granted when preliminary evidence indicates substantial improvement over existing therapies - suggesting volixibat's potential to address significant limitations of current PBC treatments like ursodeoxycholic acid and obeticholic acid.
The PSC program is especially noteworthy as this condition has no FDA-approved therapies despite affecting approximately 30,000 patients in the US alone. If successful, volixibat could become the first approved treatment for this progressive liver disease.
Mirum's expansion into Fragile X Syndrome with MRM-3379 represents a strategic diversification beyond liver diseases while maintaining focus on rare conditions with high unmet needs. This PDE4D inhibitor targets a specific mechanism implicated in FXS pathophysiology, potentially addressing cognitive and behavioral symptoms in the most common inherited form of intellectual disability.
The company's projection of positive cash flow in 2025 marks a critical inflection point, transitioning from a development-stage to a self-sustaining commercial organization - a milestone many specialty pharmaceutical companies never achieve. With
- 2024 net product sales of
- 2025 expected global net product sales of
- VISTAS study of volixibat in PSC expected to complete enrollment in second half 2025; topline data expected 2026
- CTEXLI (chenodiol) approved in the US for cerebrotendinous xanthomatosis
- Conference call to provide business updates today, February 26 at 1:30 p.m. PT/4:30 p.m. ET
“2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue,” said Chris Peetz, chief executive officer of Mirum. “We continue to expand the reach of our three commercial medicines within our patient communities and look forward to another year of strong financial performance. On top of this, we are looking forward to multiple upcoming clinical and regulatory milestones, such as PSC where we’re expecting full enrollment of our VISTAS trial in the second half of the year.”
Future Expectations and Milestones
-
2025 Guidance: expect continued revenue growth with global net product sales of approximately
$420 million $435 million - Volixibat VISTAS study in primary sclerosing cholangitis (PSC) expected to complete enrollment in second half 2025; topline data expected in 2026.
- Volixibat VANTAGE study in primary biliary cholangitis (PBC) expected to complete enrollment in 2026.
- LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions expected to complete enrollment in 2026.
- Expect to initiate Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) in 2025.
2024 Highlights
Commercial: Strong growth across all three approved medicines
-
Total net product sales of
$336.4 million -
2024 LIVMARLI net product sales totaled
$213.3 million -
2024 Bile Acid Medicines net product sales totaled
$123.1 million - Global LIVMARLI business grew to 30 countries with commercial access, including successful reimbursement negotiation and launch in the four major European markets.
Regulatory and Pipeline: Achieved multiple significant milestones and expanded pipeline
- Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC studies.
-
Volixibat granted breakthrough therapy designation for treatment of cholestatic pruritus in PBC by the
U.S. Food and Drug Administration (FDA). -
LIVMARLI approved by the FDA for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC) patients 12 months and older and in
Europe for treatment of PFIC in patients three months and older. - Initiated the LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions.
- In-licensed global rights to PDE4D inhibitor MRM-3379 for FXS.
Corporate and Financial: Strong financial performance
-
Total net product sales for the full year ended December 31, 2024, was
$336.4 million $178.9 million -
Total operating expenses were
$424.5 million $295.5 million -
Total operating expenses for the full year ended December 31, 2024 included
$79.4 million $48.8 million -
Cash, cash equivalents and investments of
$292.8 million $286.3 million
Business Update Conference Call
Mirum will host a conference call today, February 26 at 1:30 p.m. PT/4:30 p.m. ET, to provide business updates. Join the call using the following details:
Conference Call Details:
International: +1 404 975 4839
Passcode: 126145
You may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.
About LIVMARLI® (maralixibat) oral solution
LIVMARLI® (maralixibat) oral solution is an orally administered, ileal bile acid transporter (IBAT) inhibitor approved by the
LIVMARLI has received orphan designation for ALGS and PFIC. LIVMARLI is currently being evaluated in the Phase 3 EXPAND study in additional settings of cholestatic pruritus. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum’s clinical trials section on the company’s website.
IMPORTANT SAFETY INFORMATION
Limitation of Use: LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein.
LIVMARLI can cause side effects, including
Liver injury. Changes in certain liver tests are common in patients with ALGS and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or may lead to liver transplant or death. Your healthcare provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen), bloating in your stomach area, loss of appetite or bleeding or bruising more easily than normal.
Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain. Your healthcare provider may advise you to monitor for new or worsening stomach problems including stomach pain, diarrhea, blood in your stool or vomiting. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you.
A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat is common in patients with Alagille syndrome and PFIC but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment and may monitor for bone fractures and bleeding which have been reported as common side effects.
US Prescribing Information
EU SmPC
Canadian Product Monograph
About Volixibat
Volixibat is an oral, minimally absorbed agent designed to selectively inhibit the ileal bile acid transporter (IBAT). Volixibat may offer a novel approach in the treatment of adult cholestatic diseases by blocking the recycling of bile acids, through inhibition of IBAT, thereby reducing bile acids systemically and in the liver. Volixibat is currently being evaluated in Phase 2b studies for primary sclerosing cholangitis (PSC) (VISTAS study), and primary biliary cholangitis (PBC) (VANTAGE study). In June, Mirum announced positive interim results from the Phase 2b VANTAGE study showing statistically significant improvement in pruritus as well as meaningful reductions in serum bile acids and improvements in fatigue for patients treated with volixibat. No new safety signals were observed, and the most common adverse event was diarrhea with all cases mild to moderate. Volixibat has been granted breakthrough therapy designation for the treatment of PBC.
About CHOLBAM® (cholic acid) capsules
The FDA approved CHOLBAM (cholic acid) capsules in March 2015, the first FDA-approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisome biogenesis disorder-Zellweger spectrum disorder. The effectiveness of CHOLBAM has been demonstrated in clinical trials for bile acid synthesis disorders and the adjunctive treatment of peroxisomal disorders. An estimated 200 to 300 patients are current candidates for therapy.
CHOLBAM® (cholic acid) Indication
CHOLBAM is a bile acid indicated for
- Treatment of bile acid synthesis disorders due to single enzyme defects.
- Adjunctive treatment of peroxisomal disorders, including Zellweger spectrum disorders, in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat-soluble vitamin absorption.
LIMITATIONS OF USE
The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects or peroxisomal disorders, including Zellweger spectrum disorders, have not been established.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS – Exacerbation of liver impairment
Monitor liver function and discontinue CHOLBAM in patients who develop worsening of liver function while on treatment.
Concurrent elevations of serum gamma glutamyltransferase (GGT) and alanine aminotransferase (ALT) may indicate CHOLBAM overdose.
Discontinue treatment with CHOLBAM at any time if there are clinical or laboratory indicators of worsening liver function or cholestasis.
ADVERSE REACTIONS
The most common adverse reactions (≥
Please see full Prescribing Information for additional Important Safety Information.
About CTEXLI™ (chenodiol) tablets
CTEXLI™ (chenodiol) tablets is FDA-approved for the treatment of adults with cerebrotendinous xanthomatosis (CTX). Chenodiol is another name for chenodeoxycholic acid (CDCA). CDCA is a naturally occurring bile acid that was originally approved for the treatment of people with radiolucent stones in the gallbladder. CTEXLI was evaluated as part of the Phase 3 RESTORE study, the first and only clinical trial for CTX. CTX is a rare progressive disease that can affect the brain, spinal cord, tendons, eyes and arteries.
IMPORTANT SAFETY INFORMATION
CTEXLI can cause side effects, including :
Liver Injury : You will need to undergo laboratory testing before starting and while taking CTEXLI to check your liver function. Changes in certain liver tests may occur during treatment and may be a sign of liver injury. This can be serious. Stop taking CTEXLI immediately and tell your healthcare provider right away if you get any signs or symptoms of liver problems, including, stomach (abdomen) pain, bruising, dark-colored urine, feeling tired (fatigue), bleeding, yellowing of the skin and eyes, nausea, and itching.
Most Common Side Effects : Diarrhea, headache, stomach pain, constipation, high blood pressure, muscular weakness, and upper respiratory tract infection.
Tell your healthcare provider about all the medications that you take, as CTEXLI may interact with other medicines.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, significant increase or continued commercial results for our approved products, including continued financial growth, being on track to achieve our yearly financial guidance, delivering life changing medicines for patients suffering from rare diseases, the results, enrollment, conduct and progress of Mirum’s ongoing and planned studies for its product candidates, including newly in-licensed product candidates, the timing and results of interim analyses of our ongoing studies and the regulatory approval path for our product candidates in any indication or any specific territory. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “expected,” “will,” “could,” “would,” “guidance,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Mirum’s Report for the quarter ended December 31, 2024 and subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Mirum Pharmaceuticals, Inc.
|
||||||||||||||||
|
|
Three Months Ended December 31, |
|
Year Ended December 31, |
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
|
|
|
|
|
|
|
||||||||||
Revenue: |
|
|
|
|
|
|
|
|
||||||||
Product sales, net |
|
$ |
99,430 |
|
|
$ |
69,554 |
|
|
$ |
336,409 |
|
|
$ |
178,874 |
|
License and other revenue |
|
|
(16 |
) |
|
|
— |
|
|
|
479 |
|
|
|
7,500 |
|
Total revenue |
|
|
99,414 |
|
|
|
69,554 |
|
|
|
336,888 |
|
|
|
186,374 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
||||||||
Cost of sales (1) |
|
|
22,780 |
|
|
|
25,020 |
|
|
|
81,643 |
|
|
|
47,039 |
|
Research and development |
|
|
44,026 |
|
|
|
30,935 |
|
|
|
140,630 |
|
|
|
102,609 |
|
Selling, general and administrative |
|
|
56,830 |
|
|
|
46,184 |
|
|
|
202,221 |
|
|
|
145,880 |
|
Total operating expenses (2) |
|
|
123,636 |
|
|
|
102,139 |
|
|
|
424,494 |
|
|
|
295,528 |
|
Loss from operations |
|
|
(24,222 |
) |
|
|
(32,585 |
) |
|
|
(87,606 |
) |
|
|
(109,154 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
||||||||
Interest income |
|
|
3,204 |
|
|
|
3,775 |
|
|
|
13,792 |
|
|
|
13,735 |
|
Interest expense |
|
|
(3,579 |
) |
|
|
(3,563 |
) |
|
|
(14,311 |
) |
|
|
(15,105 |
) |
Loss from termination of revenue interest purchase agreement |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(49,076 |
) |
Other income (expense), net |
|
|
231 |
|
|
|
(3,061 |
) |
|
|
1,213 |
|
|
|
(2,824 |
) |
Net loss before provision for income taxes |
|
|
(24,366 |
) |
|
|
(35,434 |
) |
|
|
(86,912 |
) |
|
|
(162,424 |
) |
(Benefit from) provision for income taxes |
|
|
(576 |
) |
|
|
225 |
|
|
|
1,030 |
|
|
|
991 |
|
Net loss |
|
|
(23,790 |
) |
|
|
(35,659 |
) |
|
|
(87,942 |
) |
|
|
(163,415 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Net loss per share, basic and diluted |
|
|
|
|
|
$ |
(1.85 |
) |
|
$ |
(4.00 |
) |
||||
Weighted-average shares of common stock outstanding, basic and diluted |
|
|
|
|
|
|
47,522,594 |
|
|
|
40,885,124 |
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
(1) Amounts include intangible amortization expense as follows: |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
Intangible amortization |
|
$ |
5,894 |
|
|
$ |
5,305 |
|
|
$ |
22,783 |
|
|
$ |
10,404 |
|
|
|
|
|
|
|
|
|
|
||||||||
(2) Amounts include stock-based compensation expense as follows: |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
Cost of sales |
|
$ |
311 |
|
|
$ |
— |
|
|
$ |
948 |
|
|
$ |
— |
|
Research and development |
|
|
4,210 |
|
|
|
2,879 |
|
|
|
15,188 |
|
|
|
10,892 |
|
Selling, general and administrative |
|
|
8,730 |
|
|
|
6,841 |
|
|
|
32,308 |
|
|
|
24,131 |
|
Total stock-based compensation |
|
$ |
13,251 |
|
|
$ |
9,720 |
|
|
$ |
48,444 |
|
|
$ |
35,023 |
|
Mirum Pharmaceuticals, Inc.
|
||||||||
|
December 31, |
|||||||
|
2024 |
|
2023 |
|||||
|
|
|
|
|||||
Assets |
|
|
|
|||||
Current assets: |
|
|
|
|||||
Cash and cash equivalents |
$ |
222,503 |
|
|
$ |
286,326 |
|
|
Short-term investments |
|
57,812 |
|
|
|
— |
|
|
Accounts receivable |
|
78,286 |
|
|
|
67,968 |
|
|
Inventory |
|
22,403 |
|
|
|
22,312 |
|
|
Prepaid expenses and other current assets |
|
11,784 |
|
|
|
10,935 |
|
|
Total current assets |
|
392,788 |
|
|
|
387,541 |
|
|
Restricted cash |
|
425 |
|
|
|
— |
|
|
Long-term investments |
|
12,526 |
|
|
|
— |
|
|
Intangible assets, net |
|
249,819 |
|
|
|
252,925 |
|
|
Other noncurrent assets |
|
15,196 |
|
|
|
6,155 |
|
|
Total assets |
$ |
670,754 |
|
|
$ |
646,621 |
|
|
Liabilities and Stockholders’ Equity |
|
|
|
|||||
Current liabilities: |
|
|
|
|||||
Accounts payable |
$ |
14,618 |
|
|
$ |
7,416 |
|
|
Accrued expenses |
|
110,224 |
|
|
|
78,544 |
|
|
Operating lease liabilities, current |
|
1,709 |
|
|
|
1,104 |
|
|
Total current liabilities |
|
126,551 |
|
|
|
87,064 |
|
|
Operating lease liabilities, noncurrent |
|
7,972 |
|
|
|
617 |
|
|
Convertible notes payable, net, noncurrent |
|
308,082 |
|
|
|
306,421 |
|
|
Other liabilities |
|
2,509 |
|
|
|
3,849 |
|
|
Total liabilities |
|
445,114 |
|
|
|
397,951 |
|
|
Commitments and contingencies |
|
|
|
|||||
Stockholders’ equity: |
|
|
|
|||||
Preferred stock |
|
— |
|
|
|
— |
|
|
Common stock |
|
5 |
|
|
|
5 |
|
|
Additional paid-in capital |
|
870,189 |
|
|
|
803,260 |
|
|
Accumulated deficit |
|
(644,181 |
) |
|
|
(556,239 |
) |
|
Accumulated other comprehensive (loss) income |
|
(373 |
) |
|
|
1,644 |
|
|
Total stockholders’ equity |
|
225,640 |
|
|
|
248,670 |
|
|
Total liabilities and stockholders’ equity |
$ |
670,754 |
|
|
$ |
646,621 |
||
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226221425/en/
Investor Contacts:
Andrew McKibben
ir@mirumpharma.com
Media Contact:
Erin Murphy
media@mirumpharma.com
Source: Mirum Pharmaceuticals, Inc.
FAQ
What were Mirum Pharmaceuticals (MIRM) total net product sales in 2024?
What is MIRM's revenue guidance for 2025?
How much did LIVMARLI contribute to MIRM's 2024 revenue?
When will MIRM's VISTAS study for volixibat in PSC complete enrollment?
What was MIRM's cash position at the end of 2024?
